Suppressor of Cytokine Signaling 1 (SOCS1) (N-Term) Peptide

Details for Product No. ABIN1382351
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Protein Name
Synonyms JAB, CIS1, SSI1, TIP3, CISH1, SSI-1, SOCS-1, Cish1, Socs-1, Cish7, socs1, zgc:91868, jab, cis1, ssi1, tip3, cish1, ssi-1, socs-1, SOCS1, LOC100228306, socs1b
Protein Region
N-Term
Origin
Human
(1), (1), (5), (1), (1)
Application
Blocking Peptide (BP)
Pubmed 4 references available
Catalog no. ABIN1382351
Quantity 0.05 mg
Price
77.00 $   Plus shipping costs $45.00
Shipping to United States (Change)
Availability Will be delivered in 2 to 3 Business Days

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Characteristics 17 amino acids near the amino terminus of human SOCS1.
Human
Alternative Name SOCS1
Research Area Chromatin and Nuclear Signaling, Signaling, Cytokines
Application Notes SOCS1 peptide is used for blocking the activity of SOCS1.
Restrictions For Research Use only
Format Liquid
Concentration 200 µg/mL
Buffer PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1 % bovine serum albumin and 0.02 % sodium azide
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage -20 °C
Expiry Date 12 months
Background publications Nishiya, DeFranco: "Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors." in: The Journal of biological chemistry, Vol. 279, Issue 18, pp. 19008-17, 2004 (PubMed).

Wagner: "The immunobiology of the TLR9 subfamily." in: Trends in immunology, Vol. 25, Issue 7, pp. 381-6, 2004 (PubMed).

McGettrick, ONeill: "The expanding family of MyD88-like adaptors in Toll-like receptor signal transduction." in: Molecular immunology, Vol. 41, Issue 6-7, pp. 577-82, 2004 (PubMed).

Rakesh, Agrawal: "Controlling cytokine signaling by constitutive inhibitors." in: Biochemical pharmacology, Vol. 70, Issue 5, pp. 649-57, 2005 (PubMed).

Reactivities (1), (1), (5), (1), (1)
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Validation Images
back to top